http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 16 Jul 2026 16:06:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Inhibrx+Biosciences%2C++++++For%3A+Jul+15/26779691.html si-local-file:///var/storage/secattach/20260716/26779691.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Inhibrx+Biosciences%2C++++++For%3A+Jul+15/26779691.html Thu, 16 Jul 2026 16:06:00 -0400 INBX O.21755854 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Inhibrx+Biosciences%2C++++++For%3A+Jul+15/26779691.html si-local-file:///var/storage/secattach/20260716/26779691.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Inhibrx+Biosciences%2C++++++For%3A+Jul+15/26779691.html Thu, 16 Jul 2026 16:06:00 -0400 INBX O.21755854 http://www.streetinsider.com/Corporate+News/Inhibrx+expands+loan+facility+with+Oxford+Finance+to+%24500M/26777489.html <p>Inhibrx Biosciences, Inc. (NASDAQ: INBX) has entered into a second amendment to its loan and security agreement with Oxford Finance LLC, expanding the total credit facility to $500.0 million, according to a company statement.</p><p>The amendment adds a new tranche of up to $325.0 million in gross proceeds. Of that amount, $100.0 million was funded immediately upon execution as a Term C Loan, with up to an additional $225.0 million available in increments of $50.0 million or more at the lenders' sole discretion as a Term D Loan. Prior to the amendment, Inhibrx had drawn $175.0 million under the facility.</p><p>In connection http://www.streetinsider.com/Corporate+News/Inhibrx+expands+loan+facility+with+Oxford+Finance+to+%24500M/26777489.html Thu, 16 Jul 2026 09:01:36 -0400 INBX http://www.streetinsider.com/Press+Releases/Inhibrx+Announces+Amended+Loan+Agreement+with+Oxford+Finance%2C+Expanding+Total+Facility+to+%24500.0+Million/26777472.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:INBX" idsrc="xmltag.org" >Inhibrx Biosciences, Inc.</span> ("<span value="NASDAQ-NMS:INBX" idsrc="xmltag.org" >Inhibrx</span>" or the "Company") (Nasdaq: INBX), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced it entered into the Second Amendment (the "Second Amendment") to the Loan and Security Agreement, as amended (the "Amended LSA") with <span value="ACORN:0485524145" idsrc="xmltag.org" >Oxford Finance LLC</span> ("Oxford," together with certain of its affiliates party thereto, the "Lenders"), pursuant to which the Lenders expanded the facility to an aggregate principal amount of up to <money>$500.0 million</money> (the "Credit Facility").</p> http://www.streetinsider.com/Press+Releases/Inhibrx+Announces+Amended+Loan+Agreement+with+Oxford+Finance%2C+Expanding+Total+Facility+to+%24500.0+Million/26777472.html Thu, 16 Jul 2026 09:00:00 -0400 A.04855241 INBX O.00783133 O.21755854 http://www.streetinsider.com/Press+Releases/Inhibrx+Announces+Amended+Loan+Agreement+with+Oxford+Finance%2C+Expanding+Total+Facility+to+%24500.0+Million/26777472.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:INBX" idsrc="xmltag.org" >Inhibrx Biosciences, Inc.</span> ("<span value="NASDAQ-NMS:INBX" idsrc="xmltag.org" >Inhibrx</span>" or the "Company") (Nasdaq: INBX), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced it entered into the Second Amendment (the "Second Amendment") to the Loan and Security Agreement, as amended (the "Amended LSA") with <span value="ACORN:0485524145" idsrc="xmltag.org" >Oxford Finance LLC</span> ("Oxford," together with certain of its affiliates party thereto, the "Lenders"), pursuant to which the Lenders expanded the facility to an aggregate principal amount of up to <money>$500.0 million</money> (the "Credit Facility").</p> http://www.streetinsider.com/Press+Releases/Inhibrx+Announces+Amended+Loan+Agreement+with+Oxford+Finance%2C+Expanding+Total+Facility+to+%24500.0+Million/26777472.html Thu, 16 Jul 2026 09:00:00 -0400 A.04855241 INBX O.00783133 O.21755854 http://www.streetinsider.com/Press+Releases/Inhibrx+Announces+Amended+Loan+Agreement+with+Oxford+Finance%2C+Expanding+Total+Facility+to+%24500.0+Million/26777472.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:INBX" idsrc="xmltag.org" >Inhibrx Biosciences, Inc.</span> ("<span value="NASDAQ-NMS:INBX" idsrc="xmltag.org" >Inhibrx</span>" or the "Company") (Nasdaq: INBX), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced it entered into the Second Amendment (the "Second Amendment") to the Loan and Security Agreement, as amended (the "Amended LSA") with <span value="ACORN:0485524145" idsrc="xmltag.org" >Oxford Finance LLC</span> ("Oxford," together with certain of its affiliates party thereto, the "Lenders"), pursuant to which the Lenders expanded the facility to an aggregate principal amount of up to <money>$500.0 million</money> (the "Credit Facility").</p> http://www.streetinsider.com/Press+Releases/Inhibrx+Announces+Amended+Loan+Agreement+with+Oxford+Finance%2C+Expanding+Total+Facility+to+%24500.0+Million/26777472.html Thu, 16 Jul 2026 09:00:00 -0400 A.04855241 INBX O.00783133 O.21755854 http://www.streetinsider.com/Press+Releases/Inhibrx+Announces+Amended+Loan+Agreement+with+Oxford+Finance%2C+Expanding+Total+Facility+to+%24500.0+Million/26777472.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:INBX" idsrc="xmltag.org" >Inhibrx Biosciences, Inc.</span> ("<span value="NASDAQ-NMS:INBX" idsrc="xmltag.org" >Inhibrx</span>" or the "Company") (Nasdaq: INBX), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced it entered into the Second Amendment (the "Second Amendment") to the Loan and Security Agreement, as amended (the "Amended LSA") with <span value="ACORN:0485524145" idsrc="xmltag.org" >Oxford Finance LLC</span> ("Oxford," together with certain of its affiliates party thereto, the "Lenders"), pursuant to which the Lenders expanded the facility to an aggregate principal amount of up to <money>$500.0 million</money> (the "Credit Facility").</p> http://www.streetinsider.com/Press+Releases/Inhibrx+Announces+Amended+Loan+Agreement+with+Oxford+Finance%2C+Expanding+Total+Facility+to+%24500.0+Million/26777472.html Thu, 16 Jul 2026 09:00:00 -0400 A.04855241 INBX O.00783133 O.21755854 http://www.streetinsider.com/PRNewswire/Inhibrx+Announces+Amended+Loan+Agreement+with+Oxford+Finance%2C+Expanding+Total+Facility+to+%24500.0+Million/26777472.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:INBX" idsrc="xmltag.org" >Inhibrx Biosciences, Inc.</span> ("<span value="NASDAQ-NMS:INBX" idsrc="xmltag.org" >Inhibrx</span>" or the "Company") (Nasdaq: INBX), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced it entered into the Second Amendment (the "Second Amendment") to the Loan and Security Agreement, as amended (the "Amended LSA") with <span value="ACORN:0485524145" idsrc="xmltag.org" >Oxford Finance LLC</span> ("Oxford," together with certain of its affiliates party thereto, the "Lenders"), pursuant to which the Lenders expanded the facility to an aggregate principal amount of up to <money>$500.0 million</money> (the "Credit Facility").</p> http://www.streetinsider.com/PRNewswire/Inhibrx+Announces+Amended+Loan+Agreement+with+Oxford+Finance%2C+Expanding+Total+Facility+to+%24500.0+Million/26777472.html Thu, 16 Jul 2026 09:00:00 -0400 A.04855241 INBX O.00783133 O.21755854 http://www.streetinsider.com/PRNewswire/Inhibrx+Announces+Amended+Loan+Agreement+with+Oxford+Finance%2C+Expanding+Total+Facility+to+%24500.0+Million/26777472.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:INBX" idsrc="xmltag.org" >Inhibrx Biosciences, Inc.</span> ("<span value="NASDAQ-NMS:INBX" idsrc="xmltag.org" >Inhibrx</span>" or the "Company") (Nasdaq: INBX), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced it entered into the Second Amendment (the "Second Amendment") to the Loan and Security Agreement, as amended (the "Amended LSA") with <span value="ACORN:0485524145" idsrc="xmltag.org" >Oxford Finance LLC</span> ("Oxford," together with certain of its affiliates party thereto, the "Lenders"), pursuant to which the Lenders expanded the facility to an aggregate principal amount of up to <money>$500.0 million</money> (the "Credit Facility").</p> http://www.streetinsider.com/PRNewswire/Inhibrx+Announces+Amended+Loan+Agreement+with+Oxford+Finance%2C+Expanding+Total+Facility+to+%24500.0+Million/26777472.html Thu, 16 Jul 2026 09:00:00 -0400 A.04855241 INBX O.00783133 O.21755854 http://www.streetinsider.com/PRNewswire/Inhibrx+Announces+Amended+Loan+Agreement+with+Oxford+Finance%2C+Expanding+Total+Facility+to+%24500.0+Million/26777472.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:INBX" idsrc="xmltag.org" >Inhibrx Biosciences, Inc.</span> ("<span value="NASDAQ-NMS:INBX" idsrc="xmltag.org" >Inhibrx</span>" or the "Company") (Nasdaq: INBX), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced it entered into the Second Amendment (the "Second Amendment") to the Loan and Security Agreement, as amended (the "Amended LSA") with <span value="ACORN:0485524145" idsrc="xmltag.org" >Oxford Finance LLC</span> ("Oxford," together with certain of its affiliates party thereto, the "Lenders"), pursuant to which the Lenders expanded the facility to an aggregate principal amount of up to <money>$500.0 million</money> (the "Credit Facility").</p> http://www.streetinsider.com/PRNewswire/Inhibrx+Announces+Amended+Loan+Agreement+with+Oxford+Finance%2C+Expanding+Total+Facility+to+%24500.0+Million/26777472.html Thu, 16 Jul 2026 09:00:00 -0400 A.04855241 INBX O.00783133 O.21755854 http://www.streetinsider.com/PRNewswire/Inhibrx+Announces+Amended+Loan+Agreement+with+Oxford+Finance%2C+Expanding+Total+Facility+to+%24500.0+Million/26777472.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:INBX" idsrc="xmltag.org" >Inhibrx Biosciences, Inc.</span> ("<span value="NASDAQ-NMS:INBX" idsrc="xmltag.org" >Inhibrx</span>" or the "Company") (Nasdaq: INBX), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced it entered into the Second Amendment (the "Second Amendment") to the Loan and Security Agreement, as amended (the "Amended LSA") with <span value="ACORN:0485524145" idsrc="xmltag.org" >Oxford Finance LLC</span> ("Oxford," together with certain of its affiliates party thereto, the "Lenders"), pursuant to which the Lenders expanded the facility to an aggregate principal amount of up to <money>$500.0 million</money> (the "Credit Facility").</p> http://www.streetinsider.com/PRNewswire/Inhibrx+Announces+Amended+Loan+Agreement+with+Oxford+Finance%2C+Expanding+Total+Facility+to+%24500.0+Million/26777472.html Thu, 16 Jul 2026 09:00:00 -0400 A.04855241 INBX O.00783133 O.21755854 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Inhibrx+Biosciences%2C++++++For%3A+Jun+15/26647343.html si-local-file:///var/storage/secattach/20260615/26647343.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Inhibrx+Biosciences%2C++++++For%3A+Jun+15/26647343.html Mon, 15 Jun 2026 16:07:00 -0400 INBX O.21755854 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Inhibrx+Biosciences%2C++++++For%3A+Jun+15/26647343.html si-local-file:///var/storage/secattach/20260615/26647343.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Inhibrx+Biosciences%2C++++++For%3A+Jun+15/26647343.html Mon, 15 Jun 2026 16:07:00 -0400 INBX O.21755854 http://www.streetinsider.com/Corporate+News/Inhibrx+receives+FDA+acceptance+for+ozekibart+drug+application/26645174.html <p>Inhibrx Biosciences Inc. (NASDAQ: INBX) announced that the U.S. Food and Drug Administration has accepted its Biologics License Application for ozekibart, a treatment for patients with unresectable or metastatic conventional chondrosarcoma.</p><p>The FDA set a Prescription Drug User Fee Act goal date of April 14, 2027, and identified no filing review issues. If approved, ozekibart would become the first FDA-approved treatment for this form of bone cancer.</p><p>The application is supported by results from the ChonDRAgon study, a randomized, placebo-controlled trial involving 206 patients across 67 sites worldwide. The study met its primary endpoint, showing ozekibart achieved a 52% reduction in risk http://www.streetinsider.com/Corporate+News/Inhibrx+receives+FDA+acceptance+for+ozekibart+drug+application/26645174.html Mon, 15 Jun 2026 09:15:35 -0400 INBX http://www.streetinsider.com/FDA/Inhibrx+receives+FDA+acceptance+for+ozekibart+drug+application/26645174.html <p>Inhibrx Biosciences Inc. (NASDAQ: INBX) announced that the U.S. Food and Drug Administration has accepted its Biologics License Application for ozekibart, a treatment for patients with unresectable or metastatic conventional chondrosarcoma.</p><p>The FDA set a Prescription Drug User Fee Act goal date of April 14, 2027, and identified no filing review issues. If approved, ozekibart would become the first FDA-approved treatment for this form of bone cancer.</p><p>The application is supported by results from the ChonDRAgon study, a randomized, placebo-controlled trial involving 206 patients across 67 sites worldwide. The study met its primary endpoint, showing ozekibart achieved a 52% reduction in risk http://www.streetinsider.com/FDA/Inhibrx+receives+FDA+acceptance+for+ozekibart+drug+application/26645174.html Mon, 15 Jun 2026 09:15:35 -0400 INBX http://www.streetinsider.com/Press+Releases/Inhibrx+Announces+U.S.+FDA+Acceptance+of+BLA+for+Ozekibart+in+Patients+with+Conventional+Chondrosarcoma/26645164.html <div class="xn-content"> <ul type="disc"><li><b><i>No filing review issues identified by FDA with PDUFA goal date set for <chron>April 14, 2027</chron></i></b></li><li><b><i>If Approved, Ozekibart Would Be the First and Only FDA-Approved Treatment for Unresectable or Metastatic Conventional Chondrosarcoma </i></b></li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>June 15, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:INBX" idsrc="xmltag.org" >Inhibrx Biosciences, Inc.</span> (Nasdaq: INBX) ("<span value="NASDAQ-NMS:INBX" idsrc="xmltag.org" >Inhibrx</span>" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has accepted for filing its Biologics License Application (BLA) seeking approval of ozekibart (INBRX-109) for http://www.streetinsider.com/Press+Releases/Inhibrx+Announces+U.S.+FDA+Acceptance+of+BLA+for+Ozekibart+in+Patients+with+Conventional+Chondrosarcoma/26645164.html Mon, 15 Jun 2026 09:15:00 -0400 A.06822034 INBX O.20026344 O.21755854 http://www.streetinsider.com/Press+Releases/Inhibrx+Announces+U.S.+FDA+Acceptance+of+BLA+for+Ozekibart+in+Patients+with+Conventional+Chondrosarcoma/26645164.html <div class="xn-content"> <ul type="disc"><li><b><i>No filing review issues identified by FDA with PDUFA goal date set for <chron>April 14, 2027</chron></i></b></li><li><b><i>If Approved, Ozekibart Would Be the First and Only FDA-Approved Treatment for Unresectable or Metastatic Conventional Chondrosarcoma </i></b></li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>June 15, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:INBX" idsrc="xmltag.org" >Inhibrx Biosciences, Inc.</span> (Nasdaq: INBX) ("<span value="NASDAQ-NMS:INBX" idsrc="xmltag.org" >Inhibrx</span>" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has accepted for filing its Biologics License Application (BLA) seeking approval of ozekibart (INBRX-109) for http://www.streetinsider.com/Press+Releases/Inhibrx+Announces+U.S.+FDA+Acceptance+of+BLA+for+Ozekibart+in+Patients+with+Conventional+Chondrosarcoma/26645164.html Mon, 15 Jun 2026 09:15:00 -0400 A.06822034 INBX O.20026344 O.21755854 http://www.streetinsider.com/Press+Releases/Inhibrx+Announces+U.S.+FDA+Acceptance+of+BLA+for+Ozekibart+in+Patients+with+Conventional+Chondrosarcoma/26645164.html <div class="xn-content"> <ul type="disc"><li><b><i>No filing review issues identified by FDA with PDUFA goal date set for <chron>April 14, 2027</chron></i></b></li><li><b><i>If Approved, Ozekibart Would Be the First and Only FDA-Approved Treatment for Unresectable or Metastatic Conventional Chondrosarcoma </i></b></li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>June 15, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:INBX" idsrc="xmltag.org" >Inhibrx Biosciences, Inc.</span> (Nasdaq: INBX) ("<span value="NASDAQ-NMS:INBX" idsrc="xmltag.org" >Inhibrx</span>" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has accepted for filing its Biologics License Application (BLA) seeking approval of ozekibart (INBRX-109) for http://www.streetinsider.com/Press+Releases/Inhibrx+Announces+U.S.+FDA+Acceptance+of+BLA+for+Ozekibart+in+Patients+with+Conventional+Chondrosarcoma/26645164.html Mon, 15 Jun 2026 09:15:00 -0400 A.06822034 INBX O.20026344 O.21755854 http://www.streetinsider.com/Press+Releases/Inhibrx+Announces+U.S.+FDA+Acceptance+of+BLA+for+Ozekibart+in+Patients+with+Conventional+Chondrosarcoma/26645164.html <div class="xn-content"> <ul type="disc"><li><b><i>No filing review issues identified by FDA with PDUFA goal date set for <chron>April 14, 2027</chron></i></b></li><li><b><i>If Approved, Ozekibart Would Be the First and Only FDA-Approved Treatment for Unresectable or Metastatic Conventional Chondrosarcoma </i></b></li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>June 15, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:INBX" idsrc="xmltag.org" >Inhibrx Biosciences, Inc.</span> (Nasdaq: INBX) ("<span value="NASDAQ-NMS:INBX" idsrc="xmltag.org" >Inhibrx</span>" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has accepted for filing its Biologics License Application (BLA) seeking approval of ozekibart (INBRX-109) for http://www.streetinsider.com/Press+Releases/Inhibrx+Announces+U.S.+FDA+Acceptance+of+BLA+for+Ozekibart+in+Patients+with+Conventional+Chondrosarcoma/26645164.html Mon, 15 Jun 2026 09:15:00 -0400 A.06822034 INBX O.20026344 O.21755854 http://www.streetinsider.com/PRNewswire/Inhibrx+Announces+U.S.+FDA+Acceptance+of+BLA+for+Ozekibart+in+Patients+with+Conventional+Chondrosarcoma/26645164.html <div class="xn-content"> <ul type="disc"><li><b><i>No filing review issues identified by FDA with PDUFA goal date set for <chron>April 14, 2027</chron></i></b></li><li><b><i>If Approved, Ozekibart Would Be the First and Only FDA-Approved Treatment for Unresectable or Metastatic Conventional Chondrosarcoma </i></b></li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>June 15, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:INBX" idsrc="xmltag.org" >Inhibrx Biosciences, Inc.</span> (Nasdaq: INBX) ("<span value="NASDAQ-NMS:INBX" idsrc="xmltag.org" >Inhibrx</span>" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has accepted for filing its Biologics License Application (BLA) seeking approval of ozekibart (INBRX-109) for http://www.streetinsider.com/PRNewswire/Inhibrx+Announces+U.S.+FDA+Acceptance+of+BLA+for+Ozekibart+in+Patients+with+Conventional+Chondrosarcoma/26645164.html Mon, 15 Jun 2026 09:15:00 -0400 A.06822034 INBX O.20026344 O.21755854 http://www.streetinsider.com/PRNewswire/Inhibrx+Announces+U.S.+FDA+Acceptance+of+BLA+for+Ozekibart+in+Patients+with+Conventional+Chondrosarcoma/26645164.html <div class="xn-content"> <ul type="disc"><li><b><i>No filing review issues identified by FDA with PDUFA goal date set for <chron>April 14, 2027</chron></i></b></li><li><b><i>If Approved, Ozekibart Would Be the First and Only FDA-Approved Treatment for Unresectable or Metastatic Conventional Chondrosarcoma </i></b></li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>June 15, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:INBX" idsrc="xmltag.org" >Inhibrx Biosciences, Inc.</span> (Nasdaq: INBX) ("<span value="NASDAQ-NMS:INBX" idsrc="xmltag.org" >Inhibrx</span>" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has accepted for filing its Biologics License Application (BLA) seeking approval of ozekibart (INBRX-109) for http://www.streetinsider.com/PRNewswire/Inhibrx+Announces+U.S.+FDA+Acceptance+of+BLA+for+Ozekibart+in+Patients+with+Conventional+Chondrosarcoma/26645164.html Mon, 15 Jun 2026 09:15:00 -0400 A.06822034 INBX O.20026344 O.21755854 http://www.streetinsider.com/PRNewswire/Inhibrx+Announces+U.S.+FDA+Acceptance+of+BLA+for+Ozekibart+in+Patients+with+Conventional+Chondrosarcoma/26645164.html <div class="xn-content"> <ul type="disc"><li><b><i>No filing review issues identified by FDA with PDUFA goal date set for <chron>April 14, 2027</chron></i></b></li><li><b><i>If Approved, Ozekibart Would Be the First and Only FDA-Approved Treatment for Unresectable or Metastatic Conventional Chondrosarcoma </i></b></li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>June 15, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:INBX" idsrc="xmltag.org" >Inhibrx Biosciences, Inc.</span> (Nasdaq: INBX) ("<span value="NASDAQ-NMS:INBX" idsrc="xmltag.org" >Inhibrx</span>" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has accepted for filing its Biologics License Application (BLA) seeking approval of ozekibart (INBRX-109) for http://www.streetinsider.com/PRNewswire/Inhibrx+Announces+U.S.+FDA+Acceptance+of+BLA+for+Ozekibart+in+Patients+with+Conventional+Chondrosarcoma/26645164.html Mon, 15 Jun 2026 09:15:00 -0400 A.06822034 INBX O.20026344 O.21755854 http://www.streetinsider.com/PRNewswire/Inhibrx+Announces+U.S.+FDA+Acceptance+of+BLA+for+Ozekibart+in+Patients+with+Conventional+Chondrosarcoma/26645164.html <div class="xn-content"> <ul type="disc"><li><b><i>No filing review issues identified by FDA with PDUFA goal date set for <chron>April 14, 2027</chron></i></b></li><li><b><i>If Approved, Ozekibart Would Be the First and Only FDA-Approved Treatment for Unresectable or Metastatic Conventional Chondrosarcoma </i></b></li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>June 15, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:INBX" idsrc="xmltag.org" >Inhibrx Biosciences, Inc.</span> (Nasdaq: INBX) ("<span value="NASDAQ-NMS:INBX" idsrc="xmltag.org" >Inhibrx</span>" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has accepted for filing its Biologics License Application (BLA) seeking approval of ozekibart (INBRX-109) for http://www.streetinsider.com/PRNewswire/Inhibrx+Announces+U.S.+FDA+Acceptance+of+BLA+for+Ozekibart+in+Patients+with+Conventional+Chondrosarcoma/26645164.html Mon, 15 Jun 2026 09:15:00 -0400 A.06822034 INBX O.20026344 O.21755854 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibrx+Biosciences%2C++++++For%3A+Jun+03++Filed+by%3A+MANHARD+KIMBERLY/26606917.html si-local-file:///var/storage/secattach/20260604/26606917.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibrx+Biosciences%2C++++++For%3A+Jun+03++Filed+by%3A+MANHARD+KIMBERLY/26606917.html Thu, 04 Jun 2026 17:29:00 -0400 INBX O.21755854 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibrx+Biosciences%2C++++++For%3A+Jun+03++Filed+by%3A+MANHARD+KIMBERLY/26606917.html si-local-file:///var/storage/secattach/20260604/26606917.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibrx+Biosciences%2C++++++For%3A+Jun+03++Filed+by%3A+MANHARD+KIMBERLY/26606917.html Thu, 04 Jun 2026 17:29:00 -0400 INBX O.21755854